Bio Medica Laboratories Ltd. has approved the alteration of its object clause to support its expansion plans. The Board of Directors passed a resolution to this effect in a meeting held on June 22, 2026. The alteration involves incorporating new sub-clauses into the Main Objects of the Memorandum of Association (MoA). These changes are intended to facilitate the company's growth and are subject to approval by shareholders through the postal ballot process.

The amendments focus on expanding the company's business operations into the manufacturing, processing, and trading of essential oils and related products. The new clauses will be inserted after the existing Clause 3(a) (2) of the Main Object Clause 3(a) of the MoA. The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Amendments to the Object Clause

The proposed amendments introduce several new business activities. These include the manufacturing, extracting, refining, and trading of essential oils, aromatic oils, herbal oils, and fragrance oils. The company also seeks to deal in plant extracts, floral extracts, spice oils, oleoresins, and perfumery compounds. The scope extends to all natural, synthetic, and allied products derived from various botanical sources such as herbs, flowers, leaves, roots, seeds, and barks.

Additionally, the amendments authorize the company to act as an agent, broker, dealer, stockist, wholesaler, retailer, or franchisee for essential oils and aromatic chemicals. These products are intended for use in diverse sectors including pharmaceutical, cosmetic, personal care, food, beverage, wellness, aromatherapy, agricultural, and industrial sectors.

Infrastructure Development

To support these expanded operations, the company plans to establish, acquire, lease, operate, and maintain necessary infrastructure. This includes factories, processing units, distillation plants, extraction units, warehouses, and laboratories. These facilities will be utilized for the manufacture, processing, storage, packaging, and trading of the newly included product categories.

Bio Medica Laboratories released the subscription status for its initial public offering, showing a total subscription of 1.05 times. The demand was primarily driven by institutional investors, while other categories saw muted interest.

Subscription Breakdown

The Qualified Institutional Buyers (QIB) category recorded the highest subscription level at 15.94 times. In contrast, the retail investor category was subscribed 1.41 times. The Non-Institutional Buyers category was divided into sHNI and bHNI segments, with subscriptions of 0.45 times and 0.34 times, respectively. The employee category recorded a subscription of 0 times.

Investor Category Performance

The following table details the subscription figures across different investor categories:

The data highlights a strong preference from institutional investors compared to other segments.